|          |   | ACO                | and PCMI | H / Prima  | ary Care measures  |
|----------|---|--------------------|----------|------------|--|
| NQF<br># | Measure   | Measure<br>Steward | РСМН     | ACO        | Consensus Agreement / Notes  |
|          |   |                    | Card     | liovasculd |  |
| 0018     | Controlling High Blood Pressure<br>Description: The percentage of<br>patients 18 to 85 years of age who<br>had a diagnosis of hypertension<br>(HTN) and whose blood pressure<br>(BP) was adequately controlled<br>(<140/90) during the measurement<br>year. | NCQA               |          |            | Consensus to include either #0018 or ''N/A - Controlling High<br>Blood Pressure'' HEDIS measure in the core set if data needed for<br>either measure is available through EHR or provider self-report<br>with audit.<br><i>Note</i> : Both blood pressure control measures are included in the core set<br>with the choice being an "either/or" due to controversy <sup>i</sup> regarding the<br>2014 JAMA paper <sup>ii</sup> sometimes referred to as "JNC 8", which<br>recommends relaxing systolic blood pressure (SBP) targets to 150<br>mmHg for patients aged 60 and older without diabetes mellitus or<br>chronic kidney disease (CKD).<br>Revised ACC/AHA hypertension guidelines are expected to be released<br>later this year. Until these revised guidelines are available, a number of<br>organizations continue to recognize the 2004 Joint National Committee<br>(JNC 7) hypertension guidelines, which recommend a SBP target of<br>140 mmHg, as the national standard. Given the changing nature of<br>these guidelines, the Collaborative will revisit this measure topic when<br>the revised guidelines are available to determine which blood pressure<br>control measure aligns with the updated evidence base.<br><i>Note</i> : #0018 is specified for physician-level use. |
| N/A      | Controlling High Blood Pressure<br>(HEDIS 2016)<br>Description: The percentage of<br>members 18-85 years of age who<br>had a diagnosis of hypertension and<br>whose BP was adequately controlled<br>during the measurement year based                       | NCQA               | Ø        |            | Consensus to include either #0018 or "N/A - Controlling High<br>Blood Pressure" HEDIS measure in the core set if data needed for<br>either measure is available through EHR or provider self-report<br>with audit.<br><i>Note</i> : Both blood pressure control measures are included in the core set<br>with the choice being an "either/or" due to controversy <sup>iii</sup> regarding the<br>2014 JAMA paper <sup>iv</sup> sometimes referred to as "JNC 8", which<br>recommends relaxing systolic blood pressure (SBP) targets to 150<br>mmHg for patients aged 60 and older without diabetes mellitus or   |

|          | ACO and PCMH / Primary Care measures  |                    |      |     |   |  |  |  |  |
|----------|---|--------------------|------|-----|---|--|--|--|--|
| NQF<br># | Measure   | Measure<br>Steward | РСМН | ACO | Consensus Agreement / Notes   |  |  |  |  |
|          | on the following criteria:<br>• 18-59 = <140/90 mm Hg<br>• 60-85 w/ diabetes =<br><140/90 mm Hg<br>• 60-85 w/o diabetes =<br><150/90 mm Hg  |                    |      |     | chronic kidney disease (CKD).<br>Revised ACC/AHA hypertension guidelines are expected to be released<br>later this year. Until these revised guidelines are available, a number of<br>organizations continue to recognize the 2004 Joint National Committee<br>(JNC 7) hypertension guidelines, which recommend a SBP target of<br>140 mmHg, as the national standard. Given the changing nature of<br>these guidelines, the Collaborative will revisit this measure topic when<br>the revised guidelines are available to determine which blood pressure<br>control measure aligns with the updated evidence base.<br><i>Note:</i> Please refer to 2016 HEDIS specifications which align with the<br>recommendations in the 2014 JAMA paper <sup>v</sup> . |  |  |  |  |
| 0071     | Persistent Beta Blocker Treatment<br>After a Heart Attack<br>Description: The percentage of<br>patients 18 years of age and older<br>during the measurement year who<br>were hospitalized and discharged<br>alive from 6 months prior to the<br>beginning of the measurement year<br>through the 6 months after the<br>beginning of the measurement year<br>with a diagnosis of AMI and who<br>received persistent beta-blocker<br>treatment for six months after<br>discharge. | NCQA               | Z    | Ŋ   | Consensus to include in core set.   |  |  |  |  |

|          |  | ACO                | and PCM | H / Prima | ary Care measures   |
|----------|--|--------------------|---------|-----------|---|
| NQF<br># | Measure  | Measure<br>Steward | РСМН    | ACO       | Consensus Agreement / Notes   |
| 0068     | Ischemic Vascular Disease: Use of<br>Aspirin or Another Antithrombotic<br>Description: The percentage of<br>patients 18 years of age and older<br>who were discharged alive for acute<br>myocardial infarction (AMI),<br>coronary artery bypass graft<br>(CABG) or percutaneous coronary<br>interventions (PCI) during the 12<br>months prior to the measurement<br>year, or who had a diagnosis of<br>ischemic vascular disease (IVD)<br>during the measurement year and the<br>year prior to the measurement year<br>and who had the following during<br>the measurement year. | NCQA               |         | Ø         | <ul> <li>Consensus to include in core set for ACOs only.</li> <li>Notes: <ul> <li>Measure is to be applied only at the group level. Programs utilizing this measure are not looking for 100% performance due to concerns with patients at risk for bleeding.</li> <li>Used in Million Hearts Campaign.</li> </ul> </li> </ul> |
|          |  |                    |         | Diabete   | S   |
| 0059     | Comprehensive Diabetes Care:<br>HbA1c Poor Control (>9.0%)<br>Description: The percentage of<br>patients 18-75 years of age with<br>diabetes (type 1 and type 2) whose<br>most recent HbA1c level during the<br>measurement year was greater than<br>9.0% (poor control) or was missing<br>a result, or if an HbA1c test was not<br>done during the measurement year.  | NCQA               | V       | V         | Consensus to include in core set if data needed for this measure is<br>available through EHR or provider self-report with audit.  |

|          |   | ACO                | and PCMI | H / Prima | ary Care measures  |
|----------|---|--------------------|----------|-----------|--|
| NQF<br># | Measure   | Measure<br>Steward | РСМН     | ACO       | Consensus Agreement / Notes  |
| 0055     | Comprehensive Diabetes Care: Eye<br>Exam  | NCQA               | Ø        | V         | Consensus to include in core set. Reportable via administrative data.  |
|          | Description: The percentage of<br>patients 18-75 years of age with<br>diabetes (type 1 and type 2) who had<br>an eye exam (retinal) performed.  |                    |          |           |  |
| 0057     | Comprehensive Diabetes Care:<br>Hemoglobin A1c (HbA1c) testing  | NCQA               | Ø        | V         | Consensus to include in core set. Reportable via administrative data.  |
|          | Description: The percentage of<br>patients 18-75 years of age with<br>diabetes (type 1 and type 2) who<br>received an HbA1c test during the<br>measurement year.  |                    |          |           |  |
| 0056     | Comprehensive Diabetes Care: Foot<br>Exam   | NCQA               | Ø        | V         | Consensus to include in core set if data needed for this measure is<br>available through EHR or provider self-report with audit. |
|          | Description: The percentage of<br>patients 18-75 years of age with<br>diabetes (type 1 and type 2) who<br>received a foot exam (visual<br>inspection and sensory exam with<br>mono filament and a pulse exam)<br>during the measurement year. |                    |          |           |  |
| 0062     | Comprehensive Diabetes Care:<br>Medical Attention for Nephropathy   | NCQA               | Ø        |           | Consensus to include in core set if data needed for this measure is<br>available through EHR or provider self-report with audit. |
|          | Measure Description: The  |                    |          |           |  |

|          |   | ACO                | and PCM    | H / Prima   | ry Care measures  |
|----------|---|--------------------|------------|-------------|---|
| NQF<br># | Measure   | Measure<br>Steward | РСМН       | ACO         | Consensus Agreement / Notes   |
|          | percentage of patients 18-75 years of<br>age with diabetes (type 1 and type 2)<br>who received a nephropathy<br>screening test or had evidence of<br>nephropathy during the<br>measurement year.  |                    |            |             |   |
|          |   | 0                  | Care Coord | ination / I | Patient Safety  |
| 0097     | Medication Reconciliation<br>(Clinician measure)<br>Description; Percentage of patients<br>aged 18 years and older discharged<br>from any inpatient facility (e.g.<br>hospital, skilled nursing facility, or<br>rehabilitation facility) and seen<br>within 30 days of discharge in the<br>office by the physician, prescribing<br>practitioner, registered nurse, or<br>clinical pharmacist who had<br>reconciliation of the discharge<br>medications with the current<br>medication list in the outpatient<br>medical record documented. This<br>measure is reported as two rates<br>stratified by age group: 18-64 and | NCQA               |            |             | Consensus to include in core set for ACOs only if data needed for<br>this measure is available through EHR or provider self-report with<br>audit. |
|          | 65+.  |                    | Preven     | tion and    | Wellness  |
| 0032     | Cervical Cancer Screening<br>Description: Percentage of women   | NCQA               | Ø          | Ø           | Consensus to include in core set.   |

|          | ACO and PCMH / Primary Care measures   |                    |      |                         |  |  |  |  |  |
|----------|--|--------------------|------|-------------------------|--|--|--|--|--|
| NQF<br># | Measure  | Measure<br>Steward | РСМН | ACO                     | Consensus Agreement / Notes  |  |  |  |  |
|          | 21–64 years of age who were<br>screened for cervical cancer using<br>either of the following criteria:                 |                    |      |                         |  |  |  |  |  |
|          | • Women age 21–64 who had cervical cytology performed every 3 years.   |                    |      |                         |  |  |  |  |  |
|          | • Women age 30–64 who had cervical cytology/ HPV co-testing every 5 years.   |                    |      |                         |  |  |  |  |  |
| N/A      | Non-recommended Cervical Cancer  | NCQA               | N    | $\checkmark$            | Consensus to include in core set.  |  |  |  |  |
|          | Screening in Adolescent Females  |                    |      |                         | Note: Please refer to NCQA HEDIS measure specifications.   |  |  |  |  |
|          | Description: The percentage of<br>women under the age of 21 who<br>were screened unnecessarily for<br>cervical cancer. |                    |      |                         |  |  |  |  |  |
| 2372     | Breast Cancer Screening  | NCQA               | M    | $\mathbf{\overline{A}}$ | Consensus to include in core set.  |  |  |  |  |
|          | Description: The percentage of<br>women 50-74 years of age who had<br>a mammogram to screen for breast<br>cancer.      |                    |      |                         | <i>Note</i> : Measure specifications align with the recently updated USPSTF guidelines. The numerator reads: "One or more mammograms any time on or between October 1 two years prior to the measurement year and December 31 of the measurement year. |  |  |  |  |
| 0034     | Colorectal Cancer Screening  | NCQA               | Ø    | Ø                       | Consensus to include in core set.  |  |  |  |  |
|          | Description: The percentage of patients 50–75 years of age who had appropriate screening for colorectal cancer.        |                    |      |                         |  |  |  |  |  |

| ACO and PCMH / Primary Care measures   |  |   |  |   |  |  |  |
|--|--|---|--|---|--|--|--|
| Measure  | Measure<br>Steward   | РСМН  | ACO  | Consensus Agreement / Notes   |  |  |  |
| Preventive Care Screening: Tobacco<br>Use: Screening and Cessation   | AMA-PCPI   | Ø   | Ø  | Consensus to include in core set data if data needed for this<br>measure is available through EHR or provider self-report with<br>audit.  |  |  |  |
| Description: % of patients aged 18<br>years and older who were screened<br>for tobacco use at least once during<br>the two-year measurement period<br>AND who received cessation<br>counseling intervention if identified<br>as a tobacco user.  |  |   |  |   |  |  |  |
| Preventive Care and Screening:<br>Body Mass Index (BMI) Screening<br>and Follow-Up   | CMS  | Ø   | Ø  | Consensus to include in core set data if data needed for this<br>measure is available through EHR or provider self-report with<br>audit.  |  |  |  |
| Description: % of patients aged 18<br>years and older with a documented<br>BMI during the current encounter or<br>during the previous six months AND<br>when the BMI is outside of normal<br>parameters, a follow-up plan is<br>documented during the encounter or<br>during the previous 6 months of the<br>encounter.<br>Normal Parameters: Age 65 years<br>and older BMI > or = 23 and < 30<br>Age 18 – 64 years BMI > or = 18.5<br>and < 25. |  |   |  |   |  |  |  |
|  | Preventive Care Screening: Tobacco<br>Use: Screening and CessationDescription: % of patients aged 18<br>years and older who were screened<br>for tobacco use at least once during<br>the two-year measurement period<br>AND who received cessation<br>counseling intervention if identified<br>as a tobacco user.Preventive Care and Screening:<br>Body Mass Index (BMI) Screening<br>and Follow-UpDescription: % of patients aged 18<br>years and older with a documented<br>BMI during the current encounter or<br>during the previous six months AND<br>when the BMI is outside of normal<br>parameters, a follow-up plan is<br>documented during the encounter or<br>during the previous 6 months of the<br>encounter.Normal Parameters: Age 65 years<br>and older BMI > or = 23 and < 30<br>Age 18 - 64 years BMI > or = 18.5 | MeasureMeasure<br>StewardPreventive Care Screening: Tobacco<br>Use: Screening and CessationAMA-PCPIDescription: % of patients aged 18<br>years and older who were screened<br>for tobacco use at least once during<br>the two-year measurement period<br>AND who received cessation<br>counseling intervention if identified<br>as a tobacco user.CMSPreventive Care and Screening:<br>Body Mass Index (BMI) Screening<br>and Follow-UpCMSDescription: % of patients aged 18<br>years and older with a documented<br>BMI during the current encounter or<br>during the previous six months AND<br>when the BMI is outside of normal<br>parameters, a follow-up plan is<br>documented during the encounter or<br>during the previous 6 months of the<br>encounter.Set StewardNormal Parameters: Age 65 years<br>and older BMI > or = 23 and < 30<br>Age 18 - 64 years BMI > or = 18.5Set Steward | MeasureMeasure<br>StewardPCMHPreventive Care Screening: Tobacco<br>Use: Screening and CessationAMA-PCPIIDescription: % of patients aged 18<br>years and older who were screened<br>for tobacco use at least once during<br>the two-year measurement period<br>AND who received cessation<br>counseling intervention if identified<br>as a tobacco user.CMSIPreventive Care and Screening:<br>Body Mass Index (BMI) Screening<br>and Follow-UpCMSIDescription: % of patients aged 18<br>years and older with a documented<br>BMI during the current encounter or<br>during the previous six months AND<br>when the BMI is outside of normal<br>parameters, a follow-up plan is<br>documented during the encounter or<br>during the previous 6 months of the<br>encounter.IINormal Parameters: Age 65 years<br>and older BMI > or = 23 and < 30<br>Age 18 - 64 years BMI > or = 18.5II | MeasureMeasure<br>StewardPCMHACOPreventive Care Screening: Tobacco<br>Use: Screening and CessationAMA-PCPIIIDescription: % of patients aged 18<br>years and older who were screened<br>for tobacco use at least once during<br>the two-year measurement period<br>AND who received cessation<br>counseling intervention if identified<br>as a tobacco user.CMSIPreventive Care and Screening:<br>Body Mass Index (BMI) Screening<br>and Follow-UpCMSIIDescription: % of patients aged 18<br>years and older with a documented<br>BMI during the current encounter or<br>during the previous six months AND<br>when the BMI is outside of normal<br>parameters, a follow-up plan is<br>documented during the encounter or<br>during the previous 6 months of the<br>encounter.IIINormal Parameters: Age 65 years<br>and older BMI > or = 18.5SuIII |  |  |  |

|          |   | ACO                | and PCMI   | H / Prima | ry Care measures  |
|----------|---|--------------------|------------|-----------|---|
| NQF<br># | Measure   | Measure<br>Steward | РСМН       | ACO       | Consensus Agreement / Notes   |
|          |   |                    | Utilizatio | on & Cost | t / Overuse   |
| 0052     | Use of Imaging Studies for Low<br>Back Pain<br>Description: The percentage of<br>members with a primary diagnosis<br>of low back pain that did not have<br>an imaging study (plain x-ray, MRI,<br>CT scan) within 28 days of the<br>diagnosis.  | NCQA               | Ø          | Ø         | <b>Consensus to include in core set.</b><br><i>Note:</i> Additional / replacement measures will be considered in future iterations of the core set once available.  |
|          | •   |                    | Pati       | ent Expe  | rience  |
| 0005     | CG CAHPS (Getting Timely<br>Appointments, Care, and<br>Information; How Well Providers<br>(or Doctors) Communicate with<br>Patients; and Access to Specialists)<br>Description: The Consumer<br>Assessment of Healthcare Providers<br>and Systems Clinician & Group<br>Survey (CG-CAHPS) is a<br>standardized survey instrument that<br>asks patients to report on their<br>experiences with primary or<br>specialty care received from<br>providers and their staff in<br>ambulatory care settings over the<br>preceding 12 months. The survey<br>includes standardized questionnaires<br>for adults and children. All<br>questionnaires can be used in both | AHRQ               |            |           | Consensus to include in core set.<br>Notes: Ongoing Discussion with CMS about an all-payer survey similar<br>to H-CAHPS to address issues related to implementation cost to a<br>practice.<br>CAHPS measure included in the Medicare Shared Savings Program<br>includes the following:<br>• Getting Timely Care, Appointments, and Information<br>• How Well Your Doctors Communicate<br>• Patients' Rating of Doctor<br>• Access to Specialists<br>• Health Promotion and Education<br>• Shared Decision Making<br>• Health Status/Functional Status<br>• Stewardship of Patient Resources |

|          |   | ACO                | and PCMI | H / Prima | ary Care measures  |
|----------|---|--------------------|----------|-----------|--|
| NQF<br># | Measure   | Measure<br>Steward | РСМН     | ACO       | Consensus Agreement / Notes  |
|          | primary care and specialty care<br>settings. The adult survey is<br>administered to patients aged 18 and<br>over. The child survey is<br>administered to the parents or<br>guardians of pediatric patients under<br>the age of 18. Patients who have had<br>at least one visit during the past 12-<br>months are eligible to be surveyed.<br>The Adult CG-CAHPS Survey<br>includes one global rating item<br>and39 items in which 13 items can<br>be organized into three composite<br>measures and one global item. The<br>Child CG-CAHPS Survey includes<br>one global rating item and 54 items<br>in which 24 items can be organized<br>into five composite measures and<br>one global item. |                    |          |           |  |
|          |   | 1                  | Beh      | avioral H | Iealth   |
| 0710     | Depression Remission at 12 Months<br>Description: Adult patients age 18<br>and older with major depression or<br>dysthymia and an initial PHQ-9<br>score > 9 who demonstrate<br>remission at twelve months defined<br>as a PHQ-9 score less than 5. This<br>measure applies to both patients<br>with newly diagnosed and existing<br>depression whose current PHQ-9   | MN Comm.<br>Meas.  | N        | M         | Consensus to include in core set data if data needed for this<br>measure is available through EHR or provider self-report with<br>audit.<br><i>Note</i> : Consensus to include along with #1885. |

|          |   | ACO                | and PCM | H / Prima | ary Care measures  |
|----------|---|--------------------|---------|-----------|--|
| NQF<br># | Measure   | Measure<br>Steward | РСМН    | ACO       | Consensus Agreement / Notes  |
|          | score indicates a need for treatment.<br>This measure additionally promotes<br>ongoing contact between the patient<br>and provider as patients who do not<br>have a follow-up PHQ-9 score at<br>twelve months (+/- 30 days) are also<br>included in the denominator.  |                    |         |           |  |
| 1885     | Depression Response at Twelve<br>Months- Progress Towards<br>Remission  | MN Comm.<br>Meas.  | Ø       |           | Consensus to include in core set data if data needed for this<br>measure is available through EHR or provider self-report with<br>audit. |
|          | Description: Adult patients age 18<br>and older with major depression or<br>dysthymia and an initial PHQ-9<br>score > 9 who demonstrate a<br>response to treatment at twelve<br>months defined as a PHQ-9 score<br>that is reduced by 50% or greater<br>from the initial PHQ-9 score. This<br>measure applies to patients with<br>newly diagnosed and existing<br>depression identified during<br>measurement period whose PHQ-9<br>indicates a need for treatment. |                    |         |           | <i>Note</i> : Consensus to include along with #0710.   |
|          |   | 1                  |         | Pulmona   | ·  |
| 1799     | Medication Management for People<br>with Asthma<br>Description: The % of patients 5-64<br>years during the measurement year   | NCQA               | N       | Ŋ         | Consensus to include in core set.  |
|          | Description: The % of patients 5-64<br>years during the measurement year<br>who were identified as having   |                    |         |           |  |

|          |   | ACO                | and PCMI | H / Prima | ry Care measures                  |
|----------|---|--------------------|----------|-----------|-----------------------------------|
| NQF<br># | Measure   | Measure<br>Steward | РСМН     | ACO       | Consensus Agreement / Notes       |
|          | <ul> <li>persistent asthma &amp; were dispensed appropriate medications that they remained on during the treatment period. Two rates are reported:</li> <li>1. The % of patients who remained on a controller medication for at least 50% of their treatment period.</li> <li>2. The % of patients who remained on a controller medication for at least 75% of their treatment period.</li> </ul> |                    |          |           |                                   |
| 0058     | Avoidance of Antibiotic Treatment<br>in Adults with Acute Bronchitis<br>Description: The percentage of<br>adults 18–64 years of age with a<br>diagnosis of acute bronchitis who<br>were not dispensed an antibiotic<br>prescription.  | NCQA               | V        |           | Consensus to include in core set. |

| Future Areas for ACO and PCMH / Primary Care Measure Development  |
|---|
| Measure based on statin use guidelines  |
| CG CAHPS Smoking cessation measure (to replace the chart-review measure)  |
| PCMH has supplement to CG CAHPS. All the CAHPS surveys are under review   |
| Goals of care and patient education   |
| Unnecessary services and waste / Overuse  |
| Health related quality of life  |
| Shared-decision making  |
| Preventive diabetes measures. Monitor USPSTF pre-diabetes final report  |
| Measure stratification to address health disparities (e.g. lower age of colorectal screening for African Americans) |
| Palliative care measures for ACO/PMCH   |
| Patient reported outcomes (PROs)  |
| Pain Management measures  |
| PROs for Asthma Exacerbations   |
| Antibiotic stewardship  |
| Total cost of care (#1604) once a reliable and valid measure is mature enough for implementation                    |
| Contraceptive measures once measures are tested and are reliable at the provider level                              |
| Composite measures  |
| Substance use disorders and screening measures  |
| P22: HIV Screening of STI patients: Percentage of patients diagnosed with an acute STI who were tested for HIV.     |
| PQRS #400: Hepatitis C: One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk                         |

\*Wright JT Jr, Fine LJ, Lackland DT, Ogedegbe G, Dennison Himmelfarb CR. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014 Apr 1;160(7):499-503.

\*\*James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507–20.

<sup>i</sup> Wright JT Jr, Fine LJ, Lackland DT, Ogedegbe G, Dennison Himmelfarb CR. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014 Apr 1;160(7):499-503.

<sup>ii</sup> James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507–20.

<sup>iii</sup> Wright JT Jr, Fine LJ, Lackland DT, Ogedegbe G, Dennison Himmelfarb CR. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014 Apr 1;160(7):499-503.

<sup>iv</sup> James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA* 2014; 311: 507–20.

<sup>v</sup> Wright JT Jr, Fine LJ, Lackland DT, Ogedegbe G, Dennison Himmelfarb CR. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014 Apr 1;160(7):499-503.

|          | Chronic Cardiovascular Condition Measures  |                    |                      |   |  |  |  |
|----------|--|--------------------|----------------------|---|--|--|--|
| NQF<br># | Measure  | Measure<br>Steward | Level of<br>Analysis | Consensus Agreement / Notes   |  |  |  |
|          |  |                    | Con                  | gestive Heart Failure   |  |  |  |
| 0330     | Hospital 30-day, all-cause, risk-<br>standardized readmission rate<br>(RSRR) following heart failure<br>hospitalization  | CMS                | Facility             | Consensus reached to include measure in core set; measure to be used at<br>the facility level only. |  |  |  |
| 0229     | Hospital 30-day, all-cause, risk-<br>standardized mortality rate<br>(RSMR) following heart failure<br>(HF) hospitalization for patients<br>18 and older                          | CMS                | Facility             | Consensus reached to include measure in core set; measure to be used at<br>the facility level only. |  |  |  |
| 0081     | Heart Failure (HF): Angiotensin-<br>Converting Enzyme (ACE)<br>Inhibitor or Angiotensin<br>Receptor Blocker (ARB)<br>Therapy for Left Ventricular<br>Systolic Dysfunction (LVSD) | AMA-<br>PCPI       | Clinician            | Consensus reached to include measure in core set.   |  |  |  |
| 0083     | Heart Failure (HF): Beta-<br>Blocker Therapy for Left<br>Ventricular Systolic Dysfunction<br>(LVSD)  | AMA-<br>PCPI       | Clinician            | Consensus reached to include measure in core set.   |  |  |  |

| <b>T</b> 7 | •       | 1 0 |  |
|------------|---------|-----|--|
| VP         | rsion   |     |  |
|            | 1 31011 | 1.0 |  |

|          | Chronic Cardiovascular Condition Measures   |                    |                      |  |  |  |  |
|----------|---|--------------------|----------------------|--|--|--|--|
| NQF<br># | Measure   | Measure<br>Steward | Level of<br>Analysis | Consensus Agreement / Notes  |  |  |  |
|          |   |                    |                      | Hypertension   |  |  |  |
| 0018     | Controlling High Blood Pressure<br>Description: The percentage of<br>patients 18 to 85 years of age<br>who had a diagnosis of<br>hypertension (HTN) and whose<br>blood pressure (BP) was<br>adequately controlled (<140/90)<br>during the measurement year. | NCQA               | Clinician            | Consensus to include either #0018 or ''N/A - Controlling High Blood<br>Pressure'' HEDIS measure in the core set.<br><i>Note</i> : Both blood pressure control measures are included in the core set with the<br>choice being an "either/or" due to controversy <sup>i</sup> regarding the 2014 JAMA paper <sup>ii</sup><br>sometimes referred to as "JNC 8", which recommends relaxing systolic blood<br>pressure (SBP) targets to 150 mmHg for patients aged 60 and older without<br>diabetes mellitus or chronic kidney disease (CKD).<br>Revised ACC/AHA hypertension guidelines are expected to be released later<br>this year. Until these revised guidelines are available, a number of organizations<br>continue to recognize the 2004 Joint National Committee (JNC 7) hypertension<br>guidelines, which recommend a SBP target of 140 mmHg, as the national<br>standard. Given the changing nature of these guidelines are available to determine |  |  |  |
|          |   |                    |                      | which blood pressure control measure aligns with the updated evidence base.<br><i>Note</i> : #0018 is specified for physician-level use.   |  |  |  |

|           | Λ  |
|-----------|----|
| Version 1 | .U |

|          | Chronic Cardiovascular Condition Measures  |                    |   |   |  |  |  |
|----------|--|--------------------|---|---|--|--|--|
| NQF<br># | Measure  | Measure<br>Steward | Level of<br>Analysis                            | Consensus Agreement / Notes   |  |  |  |
| N/A      | Controlling High Blood Pressure<br>(HEDIS 2016)<br>Measure Description: The<br>percentage of members 18-85<br>years of age who had a diagnosis<br>of hypertension and whose BP<br>was adequately controlled during<br>the measurement year based on<br>the following criteria:<br>• 18-59 = <140/90 mm Hg<br>• 60-85 w/ diabetes =<br><140/90 mm Hg<br>• 60-85 w/o diabetes =<br><150/90 mm Hg | NCQA               | Health<br>Plan/Integrated<br>Delivery<br>System | <ul> <li>Consensus to include either #0018 or "N/A - Controlling High Blood<br/>Pressure" HEDIS measure in the core set.</li> <li>Note: Both blood pressure control measures are included in the core set with the<br/>choice being an "either/or" due to controversy<sup>iii</sup> regarding the 2014 JAMA<br/>paper<sup>iv</sup> sometimes referred to as "JNC 8", which recommends relaxing systolic<br/>blood pressure (SBP) targets to 150 mmHg for patients aged 60 and older<br/>without diabetes mellitus or chronic kidney disease (CKD).</li> <li>Revised ACC/AHA hypertension guidelines are expected to be released later<br/>this year. Until these revised guidelines are available, a number of organizations<br/>continue to recognize the 2004 Joint National Committee (JNC 7) hypertension<br/>guidelines, which recommend a SBP target of 140 mmHg, as the national<br/>standard. Given the changing nature of these guidelines are available to determine<br/>which blood pressure control measure aligns with the updated evidence base.</li> <li>Note: Please refer to 2016 HEDIS specifications which align with the<br/>recommendations in the 2014 JAMA paper<sup>v</sup>.</li> <li>Note: "N/A - Controlling High Blood Pressure" HEDIS measure is specified for<br/>the health plan or integrated delivery network level use.</li> </ul> |  |  |  |

Version 1.0

|          | Chronic Cardiovascular Condition Measures  |   |                           |   |  |  |  |
|----------|--|---|---------------------------|---|--|--|--|
| NQF<br># | Measure  | Measure<br>Steward                        | Level of<br>Analysis      | Consensus Agreement / Notes   |  |  |  |
|          |  |   | Ischemic Heart l          | Disease / Coronary Heart Disease  |  |  |  |
| 0066     | Chronic Stable Coronary Artery<br>Disease: ACE Inhibitor or ARB<br>TherapyDiabetes or Left<br>Ventricular Systolic Dysfunction<br>(LVEF <40%)                  | American<br>College of<br>Cardiology      | Clinician                 | Consensus reached to include measure in core set.   |  |  |  |
| 0067     | Chronic Stable Coronary Artery<br>Disease: Antiplatelet Therapy  | American<br>College of<br>Cardiology      | Clinician                 | Consensus reached to include measure in core set.   |  |  |  |
| 0070     | Chronic Stable Coronary Artery<br>Disease: Beta-Blocker Therapy<br>Prior Myocardial Infarction (MI)<br>or Left Ventricular Systolic<br>Dysfunction (LVEF <40%) | AMA-<br>PCPI                              | Clinician                 | Consensus reached to include measure in core set. <i>Note:</i> Measure also listed under Acute MI.  |  |  |  |
| 2558     | Hospital 30-Day, All-Cause,<br>Risk-Standardized Mortality<br>Rate (RSMR) Following<br>Coronary Artery Bypass Graft<br>(CABG) Surgery                          | CMS                                       | Facility                  | Consensus reached to include measure in core set; report either #2558 or #0019; measure to be used at the facility level only.                  |  |  |  |
| 0119     | Risk-Adjusted Operative<br>Mortality for CABG  | The<br>Society of<br>Thoracic<br>Surgeons | Clinician and<br>Facility | Consensus reached to include measure in core set; report either #2558 or #0019; measure to calculated at both the physician and facility level. |  |  |  |
| 2515     | Hospital 30-day, all-cause,<br>unplanned, risk-standardized<br>readmission rate (RSRR)<br>following coronary artery bypass<br>graft (CABG) surgery             | CMS                                       | Facility                  | Consensus reached to include measure in core set; report either #2515 or #2514.   |  |  |  |

Version 1.0

| _        |  |   |                      |  |  |  |  |
|----------|--|---|----------------------|--|--|--|--|
|          | Chronic Cardiovascular Condition Measures  |   |                      |  |  |  |  |
| NQF<br># | Measure  | Measure<br>Steward                        | Level of<br>Analysis | Consensus Agreement / Notes  |  |  |  |
| 2514     | Risk-Adjusted Coronary Artery<br>Bypass Graft (CABG)<br>Readmission Rate (30-days) | The<br>Society of<br>Thoracic<br>Surgeons | Facility             | Consensus reached to include measure in core set; report either #2515 or #2514.                                  |  |  |  |
|          | Atrial fibrillation  |   |                      |  |  |  |  |
| 1525     | Chronic Anticoagulation<br>Therapy   | American<br>College of<br>Cardiology      | Clinician            | Consensus reached to include measure in core set.  |  |  |  |
|          | Prevention   |   |                      |  |  |  |  |
| 0028     | Preventive Care & Screening:<br>Tobacco Use: Screening &<br>Cessation Intervention | AMA-<br>PCPI                              | Clinician            | Consensus reached to include measure in core set. <i>Note:</i> Included in ACO and PMCH / Primary Care core set. |  |  |  |

|          | Acute Cardiovascular Condition Measures  |                    |                      |  |  |  |  |
|----------|--|--------------------|----------------------|--|--|--|--|
| NQF<br># | Measure  | Measure<br>Steward | Level of<br>Analysis | Notes & Comments   |  |  |  |
|          | Acute Myocardial Infarction  |                    |                      |  |  |  |  |
| 0505     | Hospital 30-day all-cause risk-<br>standardized readmission rate<br>(RSRR) following acute<br>myocardial infarction (AMI)<br>hospitalization | CMS                | Facility             | Consensus reached to include measure in core set; measure to be used at the facility level only. |  |  |  |
| 0163     | Primary PCI received within 90   | CMS                | Facility             | Consensus reached to include measure in core set.  |  |  |  |

| . 7 |         | Δ       |
|-----|---------|---------|
| Ve  | rsion   | 0       |
|     | 1 91011 | <br>••• |

|          | Acute Cardiovascular Condition Measures  |                                      |                      |   |  |  |  |  |
|----------|--|--------------------------------------|----------------------|---|--|--|--|--|
| NQF<br># | Measure  | Measure<br>Steward                   | Level of<br>Analysis | Notes & Comments  |  |  |  |  |
|          | minutes of hospital arrival  |                                      |                      |   |  |  |  |  |
| 0070     | Coronary Artery Disease (CAD):<br>Beta-Blocker Therapy—Prior<br>Myocardial Infarction (MI) or Left<br>Ventricular Systolic Dysfunction<br>(LVEF <40%)  | AMA-<br>PCPI                         | Clinician            | Consensus reached to include measure in core set.<br><i>Note:</i> Measure also listed under chronic CAD section.                              |  |  |  |  |
| 0230     | Hospital 30-day, all-cause, risk-<br>standardized mortality rate<br>(RSMR) following acute<br>myocardial infarction (AMI)<br>hospitalization for patients 18 and<br>older  | CMS                                  | Facility             | Consensus reached to include measure in core set.   |  |  |  |  |
| 0536     | 30-day all-cause risk-standardized<br>mortality rate following<br>Percutaneous Coronary<br>Intervention (PCI) for patients with<br>ST segment elevation myocardial<br>infarction (STEMI) or cardiogenic<br>shock                 | American<br>College of<br>Cardiology | Facility             | Consensus reached to include measure in core set.<br><i>Note:</i> #0536 is always to be reported with the complementary measure #0535.        |  |  |  |  |
| 0535     | 30-day all-cause risk-<br>standardized mortality rate<br>following percutaneous<br>coronary intervention (PCI) for<br>patients without ST segment<br>elevation myocardial infarction<br>(STEMI) and without<br>cardiogenic shock | American<br>College of<br>Cardiology | Facility             | <b>Consensus reached to include measure in core set.</b><br><i>Note:</i> #0535 is always to be reported with the complementary measure #0536. |  |  |  |  |

#### Version 1.0

|          | Acute Cardiovascular Condition Measures  |                                      |                      |   |  |  |  |
|----------|--|--------------------------------------|----------------------|---|--|--|--|
| NQF<br># | Measure  | Measure<br>Steward                   | Level of<br>Analysis | Notes & Comments  |  |  |  |
|          |  |                                      |                      | Angioplasty and Stents  |  |  |  |
| 0964     | Therapy with aspirin, P2Y12<br>inhibitor, and statin at discharge<br>following PCI in eligible patients                      | American<br>College of<br>Cardiology | Facility             | Consensus reached to include measure in core set.   |  |  |  |
| 2459     | In-hospital Risk Adjusted Rate of<br>Bleeding Events for Patients<br>Undergoing PCI  | American<br>College of<br>Cardiology | Facility             | Consensus reached to include measure in core set; measure to be used at the facility level only.  |  |  |  |
|          |  |                                      | Impla                | ntable Cardiac Defibrillators   |  |  |  |
| 0694     | Hospital Risk-Standardized<br>Complication Rate following<br>Implantation of Implantable<br>Cardioverter-Defibrillator (ICD) | American<br>College of<br>Cardiology | Facility             | Consensus reached to include measure in core set.   |  |  |  |
|          |  |                                      | (                    | Cardiac Catheterization   |  |  |  |
| 0715     | Standardized adverse event ratio<br>for children < 18 years of age<br>undergoing cardiac catheterization                     | Boston<br>Children´s<br>Hospital     | Facility             | Consensus to include in core set however measure may be subject to small<br>numbers so should be implemented only when there is adequate sample size. |  |  |  |
|          |  |                                      | 1                    | Pediatric Heart Surgery   |  |  |  |
| 0733     | Operative Mortality Stratified by<br>the Five STS-EACTS Mortality<br>Categories  | Society of<br>Thoracic<br>Surgeons   | Clinician            | Consensus to include in core set however measure may be subject to small<br>numbers so should be implemented only when there is adequate sample size. |  |  |  |

Version 1.0

|          | Future Measure for Cardiovascular Care Measure Set Inclusion   |                                   |   |  |  |  |  |  |
|----------|--|-----------------------------------|---|--|--|--|--|--|
| NQF<br># | Measure  | Measure Steward                   | Notes & Comments  |  |  |  |  |  |
| 0541     | Proportion of Days Covered (PDC): 3 Rates by<br>Therapeutic Category   | PQA                               | Consensus to include in the future pending better availability of data.<br><i>Rationale:</i> It may be difficult to accurately calculate this measure for some providers because of the way their EMRs track medications and their refills. Additionally, this measure may not be appropriate for all hypertension patients as not all are prescribed medications for diabetes.<br>Measure aligns with CMS Stars and health plans collect measure data; Population is important to monitor. |  |  |  |  |  |
| 2377     | Defect Free Care for AMI (Composite Measure)   | American College<br>of Cardiology |   |  |  |  |  |  |
| N/A      | Clinician Level Companion Measure to (0694)<br>Hospital Risk-Standardized Complication Rate<br>following Implantation of Implantable<br>Cardioverter-Defibrillator (ICD) | ACC                               | Submitted to NQF for endorsement. Review in July, 2015.   |  |  |  |  |  |
| 2439     | Post-Discharge Appointment for Heart Failure<br>Patients   | TJC                               | Data collection is currently challenging. Reconsider measure upon measure updates.  |  |  |  |  |  |
| 0671     | Cardiac Stress Imaging Not Meeting<br>Appropriate Use Criteria: Routine Testing<br>after Percutaneous Coronary Intervention  | American College<br>of Cardiology |   |  |  |  |  |  |

#### Version 1.0

#### **Future Areas for Cardiovascular Care Measure Development**

Heart Failure:

- Evidence-based anticoagulation status -- ACC note: Not all HF patients are on anticoagulants
- Outpatient symptom control or change in symptoms
- Functional status or quality of life measure for patients with heart failure.
  - Seattle Angina Questionnaire. Update is slow but can consider in work group
- Goals of care (does not need to be specific to heart failure)
- Follow-up visit after hospitalization by PCP
- End of life measures for heart failure
- Management of women with peripartum cardiomyopathy
- Proportion of days covered for beta blocker therapy: Heart Failure patients

#### Hypertension:

• Renal function measures (e.g., creatinine measures)

#### Other:

- Lipid measure based on new guidelines. With changes in guidelines and pending evidence, not yet comfortable adding lipid measures until medical consensus is reached. New data coming out which push levels back towards previous guidelines.
- Additional cost and over-utilization measures.
- Rehabilitation measures
- Mental health measures following cardiovascular events
- Symptom Management measures
- Disparities in cardiovascular care
- ICD counseling and appropriate use of ICDs measure. Article in JAMA noting severe underutilizations of ICDs in women and elderly.

<sup>&</sup>lt;sup>i</sup> Wright JT Jr, Fine LJ, Lackland DT, Ogedegbe G, Dennison Himmelfarb CR. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014 Apr 1;160(7):499-503.

<sup>&</sup>lt;sup>ii</sup> James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA* 2014; 311: 507–20.

<sup>iii</sup> Wright JT Jr, Fine LJ, Lackland DT, Ogedegbe G, Dennison Himmelfarb CR. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014 Apr 1;160(7):499-503.

<sup>iv</sup> James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA* 2014; 311: 507–20.

<sup>v</sup> Wright JT Jr, Fine LJ, Lackland DT, Ogedegbe G, Dennison Himmelfarb CR. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014 Apr 1;160(7):499-503.

### Consensus Core Set: Gastroenterology Measures Version 1.0

|              | Consensu  | s Core Set: Gastroent  | erology Measu        | ires   |
|--------------|---|------------------------|----------------------|--|
| NQF #        | Measure   | Measure Steward        | Level of<br>Analysis | Consensus Agreement / Notes  |
|              | Endos   | copy & Polyp Surveille | ince Measures        |  |
| 0658         | Appropriate Follow-Up Interval for Normal<br>Colonoscopy in Average Risk Patients                                   | AGA                    | Clinician            | Consensus to include in core set.  |
| 0659         | Colonoscopy Interval for Patients with a<br>History of Adenomatous Polyps- Avoidance<br>of Inappropriate Use        | AGA                    | Clinician            | Consensus to include in core set.  |
| PQRS<br>#343 | Screening Colonoscopy Adenoma Detection<br>Rate Measure.  | ASGE                   |                      | Consensus to include in core set.  |
| PQRS<br>#439 | Age Appropriate Screening Colonoscopy   | AGA                    | Clinician            | Consensus to include in core set for<br>measurement at the group level.            |
|              |   |                        |                      | <b>Note:</b> Programs utilizing this measure are not looking for 100% performance. |
|              |   | Inflammatory Bowel     | Disease              |  |
| PQRS<br>#271 | IBD: Preventive Care: Corticosteroid Related<br>Iatrogenic Injury – Bone Loss Assessment*                           | AGA                    | Clinician            | Consensus to include in core set.  |
| PQRS<br>#275 | IBD: Assessment of Hepatitis B Virus (HBV)<br>Status Before Initiating Anti-TNF (Tumor<br>Necrosis Factor) Therapy* | AGA                    | Clinician            | Consensus to include in core set.  |

\* Note: For 2015 PQRS, a "global denominator" was added to the IBD Measures Group. AGA intends to submit its IBD measures for NQFendorsement consideration after there are adequate testing data to meet NQF measure evaluation criteria.

### Consensus Core Set: Gastroenterology Measures Version 1.0

|       | Hepatitis C Mea  | sures for the G    | astroenterolog       | gy Core Measure Set               |
|-------|--|--------------------|----------------------|-----------------------------------|
| NQF # | Measure  | Measure<br>Steward | Level of<br>Analysis | Notes                             |
| N/A   | PQRS #401: Screening for Hepatocellular<br>Carcinoma (HCC) in Patients with<br>Hepatitis C Cirrhosis | AGA                | Clinician            | Consensus to include in core set. |
| N/A   | PQRS #400: Hepatitis C: One-Time<br>Screening for Hepatitis C Virus<br>(HCV) for Patients at Risk    | AMA-PCPI           | Clinician            | Consensus to include in core set. |

### Future Areas for Consideration or Measure Development

- #0635 Chronic Liver Disease Hepatitis A Vaccination / Proof of prior vaccination
- #0034 Colorectal Cancer Screening measure needs to retooled for GI specialists as they don't take care of a general population
- Adverse events related to colonoscopy screening (i.e., ER or hospital after a procedure, perforation, hemorrhage etc.)
- Assessing the quality of the colonoscopy:
  - Patient Safety measure: #2539 Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy
  - Consideration of CMS measure under development for Post Colonoscopy Complications
  - "Quality colonoscopy" AGA set of measures
- GERD and cirrhosis measures
- Barrett's Esophagus

[2]

|                     |  | Table 1. HI                  | V Measures           |   |
|---------------------|--|------------------------------|----------------------|---|
| NQF #               | Measure  | Measure<br>Steward           | Level of<br>Analysis | Consensus Agreement / Notes   |
| 0405                | HIV/AIDS: Pneumocystis jiroveci pneumonia<br>(PCP) Prophylaxis   | NCQA                         | Clinician            | Consensus reached for inclusion in core set.  |
| 0409                | HIV/AIDS: Sexually Transmitted Diseases –<br>Screening for Chlamydia, Gonorrhea, and<br>Syphilis           | NCQA                         | Clinician            | Consensus reached for inclusion in core set.  |
| 2082                | HIV viral load suppression   | HRSA -<br>HIV/AIDS<br>Bureau | Clinician            | Consensus reached for inclusion in core set.  |
| 2079                | HIV medical visit frequency  | HRSA -<br>HIV/AIDS<br>Bureau | Clinician            | Consensus reached for inclusion in core set.  |
| 0579                | Annual cervical cancer screening or follow-up<br>in high-risk women  | Resolution<br>Health, Inc.   | Clinician            | Consensus reached for inclusion in core set.Note: This measure may require updating if better<br>scientific evidence becomes available. |
| N/A<br>PQRS<br>#P22 | HIV Screening of STI patients: Percentage of patients diagnosed with an acute STI who were tested for HIV. | CDC                          | Clinician            | Consensus reached for inclusion in core set.  |

|       |  | Table 2. Hepatit   | is C Measures        |   |
|-------|--|--------------------|----------------------|---|
| NQF # | Measure  | Measure<br>Steward | Level of<br>Analysis | Notes   |
| N/A   | PQRS #401: Screening for Hepatocellular<br>Carcinoma (HCC) in Patients with Hepatitis C<br>Cirrhosis | AGA                | Clinician            | General consensus reached for inclusion in core set.<br><i>Note:</i> This measure may require updating if better scientific evidence becomes available. |
| N/A   | PQRS #400: Hepatitis C: One-Time Screening<br>for Hepatitis C Virus (HCV) for Patients at Risk       | AMA-PCPI           | Clinician            | Consensus reached for inclusion in core set.  |

#### Table 3. Gap Areas for Future HIV/Hepatitis C Measure Development

#### HIV

- HIV RNA Level (revise NQF #0404 CD4 Cell Count or Percentage Performed to assess HIV RNA Level which is now recognized as the key metric)
- #0413 HIV/AIDS: Screening for High Risk Sexual Behaviors (NCQA) had endorsement removed in 2013
- #0573 HIV Screening: Members at High Risk of HIV (Health Benchmarks IMS Health) had endorsement removed in 2014
- P23 HIV: Ever Screened for HIV: Percentage of persons 15-65 ever screened for HIV. Reconsider upon release of additional testing data likely in summer or fall of 2016. Less than 100% performance expected.
- Updated medical visit frequency measurement with virtual visits (#2079)
- Follow up for patients diagnosed with HIV and with low viral load

#### Hepatitis C

- #0393 Hepatitis C: Testing for Chronic Hepatitis C Confirmation of Hepatitis C Viremia
- Testing of viral load 12 weeks post-end of treatment (AGA currently revising this measure)

### Consensus Core Set: Medical Oncology Measures Version 1.0

|          | I  | Medical Oncolog  | y Core Measure       | Set  |
|----------|--|--|----------------------|--|
| NQF<br># | Measure Name   | Measure<br>Steward   | Level of<br>Analysis | Consensus Agreement / Notes  |
|          |  | Breast   | t Cancer             |  |
| 0559     | Combination chemotherapy is considered or<br>administered within 4 months (120 days) of<br>diagnosis for women under 70 with AJCC<br>T1c, or Stage II or III hormone receptor<br>negative breast cancer. | American<br>College of<br>Surgeons                             | Facility             | Consensus to include measure in core set if data<br>needed for this measure is available through EHR<br>or provider self-report with audit.  |
| 1857     | Patients with breast cancer and negative or<br>undocumented human epidermal growth<br>factor receptor 2 (HER2) status who are<br>spared treatment with trastuzumab                                       | ASCO   | Clinician            | Consensus to include measure in core set.  |
| 1858     | Trastuzumab administered to patients with<br>AJCC stage I (T1c) – III and human<br>epidermal growth factor receptor 2 (HER2)<br>positive breast cancer who receive adjuvant<br>chemotherapy              | ASCO   | Clinician            | Consensus to include measure in core set.  |
|          |  | Colorec  | tal Cancer           |  |
| 0223     | Adjuvant chemotherapy is considered or<br>administered within 4 months (120 days) of<br>diagnosis to patients under the age of 80<br>with AJCC III (lymph node positive) colon<br>cancer                 | Commission<br>on Cancer,<br>American<br>College of<br>Surgeons | Facility             | Consensus to include measure in core set if data<br>needed for this measure is available through EHR<br>or provider self-report with audit.Note:Workgroup will consider a physician-level<br>measure once available. |
| 1859     | KRAS gene mutation testing performed for<br>patients with metastatic colorectal cancer<br>who receive anti-epidermal growth factor<br>receptor monoclonal antibody therapy                               | ASCO   | Clinician            | Consensus to include measure in core set.  |

#### Consensus Core Set: Medical Oncology Measures Version 1.0

|          |  | ver                                    | sion 1.0             |   |
|----------|--|--|----------------------|---|
|          |  | Medical Oncolog                        | gy Core Measure      | Set   |
| NQF<br># | Measure Name   | Measure<br>Steward                     | Level of<br>Analysis | Consensus Agreement / Notes   |
| 1860     | Patients with metastatic colorectal cancer<br>and KRAS gene mutation spared treatment<br>with anti-epidermal growth factor receptor<br>monoclonal antibodies | ASCO                                   | Clinician            | Consensus to include measure in core set.   |
|          |  | Hospice                                | / End of Life        |   |
| 0210     | Proportion receiving chemotherapy in the last 14 days of life  | ASCO                                   | Clinician            | Consensus to include measure in core set.   |
| 0211     | Proportion with more than one emergency<br>room visit in the last 30 days of life  | ASCO                                   | Clinician            | Consensus to include measure in core set.   |
| 0213     | Proportion admitted to the ICU in the last 30 days of life   | ASCO                                   | Clinician            | Consensus to include measure in core set.   |
| 0215     | Proportion not admitted to hospice   | ASCO                                   | Clinician            | Consensus to include measure in core set.   |
| 0216     | Proportion admitted to hospice for less than 3 days  | ASCO                                   | Clinician            | Consensus to include measure in core set.   |
| 0384     | Oncology: Pain Intensity Quantified –<br>Medical Oncology and Radiation Oncology   | AMA-PCPI                               | Clinician            | Consensus to include measure in core set.   |
|          |  | Prosta                                 | te Cancer            |   |
| 0389     | Prostate Cancer: Avoidance of Overuse of<br>Bone Scan for Staging Low Risk Prostate<br>Cancer Patients   | AMA-PCPI                               | Clinician            | Consensus to include measure in core set if data<br>needed for this measure is available through EHR<br>or provider self-report with audit. |
|          |  |  |                      | <i>Note</i> : Related to Choosing Wisely Concept #2.  |
| 1853     | Radical Prostatectomy Pathology Reporting  | College of<br>American<br>Pathologists | Clinician            | Consensus to include measure in core set.   |

#### FUTURE AREAS FOR MEDICAL ONCOLOGY MEASURE DEVELOPMENT

- Pain control
- Functional status or quality of life
- Shared decision-making
- Appropriate use of chemotherapy
- Under or overtreatment (will need to develop a baseline or a threshold based on data)
- ER utilization
- In patient hospital admission rate
- Reporting of cancer stage
- Disease free survival for X number of years.
- Patient experience / PRO for level of pain experienced by patient
- Cost measures
- Lung Cancer
- Five year cure rate
- 0390: Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients Not included in the core set at present, but would like to reevaluate once better data/systems become available to collect necessary information and measure denominator issues are resolved.
- ASCO / ABIM Choosing Wisely list: Metrics included are of value and should be pushed to measure development.
  - Concept #2 is addressed in the core set in measure #0389.
  - Concept #10 is a valuable metric.
  - Concept #7 is of lower priority.

Note: The Workgroup emphasized the need to move from "check-box" process measures to outcomes measures.

The Workgroup acknowledged several challenges with selecting measures for this set:

- *Data Challenges* Currently, health plans cannot readily access data for many of these measures as they require pharmacy data (which may not be available due to carve-outs), access to patient charts, or date of death data.
- *Future Measurement Needs* Data suggests that oncology treatments change rapidly and measurement needs must be continually reassessed based on the changing protocols for treatment.

### Consensus OB/GYN Measures Version 1.0

|       |   | <b>OB/GYN</b>                       | Core Measure Set for Ambulatory Care Setting                                      |
|-------|---|-------------------------------------|---|
| NQF # | Measure   | Measure<br>Steward                  | Consensus Agreement / Notes   |
| 1391  | Frequency of Ongoing<br>Prenatal Care                                 | NCQA                                | Consensus to include in core set; measure to be used at the physician level only. |
| 0032  | Cervical Cancer Screening   | NCQA                                | Consensus to include in core set.   |
| N/A   | Non-recommended Cervical<br>Cancer Screening in<br>Adolescent Females | NCQA                                | Consensus to include in core set. <i>Note:</i> Use HEDIS specifications.          |
| 1395  | Chlamydia Screening and<br>Follow Up                                  | NCQA                                | Consensus to include in core set.   |
| 2372  | Breast Cancer Screening   | NCQA                                | Consensus to include in core set; measure to be used at the physician level only. |
| 0567  | Appropriate Work Up Prior to<br>Endometrial Ablation<br>Procedure     | Health<br>Benchmarks<br>-IMS Health | Consensus to include in core set; measure to be used at the physician level only. |

|          |   | OB/GYN                              | Core Measures for Hospital / Acute Care Settings |
|----------|---|-------------------------------------|--|
| NQF<br># | Measure   | Measure<br>Steward                  | Notes & Comments                                 |
| 0470     | Incidence of Episiotomy   | Christiana<br>Care Health<br>System | Consensus to include in core set.                |
| 0469     | PC-01 Elective Delivery<br>(Patients with elective vaginal<br>deliveries or elective cesarean | The Joint<br>Commission             | Consensus to include in core set.                |

### Consensus OB/GYN Measures Version 1.0

|          |   | OB/GYN                  | Core Measures for Hospital / Acute Care Settings |
|----------|---|-------------------------|--|
| NQF<br># | Measure   | Measure<br>Steward      | Notes & Comments                                 |
|          | sections at >= 37 and < 39<br>weeks of gestation completed)   |                         |  |
| 0471     | PC-02 Cesarean Section<br>(Nulliparous women with a<br>term, singleton baby in a<br>vertex position delivered by<br>cesarean section)   | The Joint<br>Commission | Consensus to include in core set.                |
| 0476     | PC-03 Antenatal Steroids<br>(Patients at risk of preterm<br>delivery at >=24 and <32<br>weeks gestation receiving<br>antenatal steroids prior to<br>delivering preterm newborns)  | The Joint<br>Commission | Consensus to include in core set.                |
| 0480     | PC-05 Exclusive Breast Milk<br>Feeding and the subset<br>measure<br>(The measure is reported as an<br>overall rate which includes all<br>newborns that were<br>exclusively fed breast milk<br>during the entire<br>hospitalization, and a second<br>rate, a subset of the first,<br>which includes only those<br>newborns that were | The Joint<br>Commission | Consensus to include in core set.                |

### Consensus OB/GYN Measures Version 1.0

|          |                                 | OB/GYN (           | Core Measures for Hospital / Acute Care Settings |
|----------|---------------------------------|--------------------|--|
| NQF<br># | Measure                         | Measure<br>Steward | Notes & Comments                                 |
|          | exclusively fed breast milk     |                    |  |
|          | during the entire               |                    |  |
|          | hospitalization excluding those |                    |  |
|          | whose mothers chose not to      |                    |  |
|          | breast feed.)                   |                    |  |

#### **Future Areas for Measure Development**

- Physician-level Urinary Incontinence (NCQA's physician-level UI measure did not receive endorsement and NCQA indicated they had no future plans to revise or update measure at this time).
- Cesarean Section (including time of decision for c-section and surgery start time). Data not available via claims.
- Tdap/Influenza Administration in Pregnancy (Upcoming from CDC). Need to consider data capture methods to measure vaccinations outside of typical medical settings.
- P22 HIV Screening of STI patients: Percentage of patients diagnosed with an acute STI who were tested for HIV. Considerations regarding age limit and child/adolescent privacy are necessary.

|      |   | Orthopedic Measure  | ures   |
|------|---|---|--|
| NQF# | Measure Title   | Measure Steward   | Consensus Agreement / Notes                        |
| 1550 | Hospital-level risk-standardized<br>complication rate (RSCR) following<br>elective primary total hip arthroplasty<br>(THA) and/or total knee arthroplasty<br>(TKA)  | CMS   | Consensus to include this measure in the core set. |
| 1551 | Hospital-level 30-day, all-cause risk-<br>standardized readmission rate (RSRR)<br>following elective primary total hip<br>arthroplasty (THA) and/or total knee<br>arthroplasty (TKA)  | CMS   | Consensus to include this measure in the core set. |
| 1741 | Patient Experience with Surgical Care<br>Based on the Consumer Assessment of<br>Healthcare Providers and Systems<br>(CAHPS®) Surgical Care Survey<br>We recommend the following 5<br>composites and 1 single-item measure<br>that are generated from the Consumer<br>Assessment of Healthcare Providers and<br>Systems (CAHPS®) Surgical Care<br>Survey. Each measure is used to assess<br>a particular domain of surgical care<br>quality from the patient's perspective.<br>Measure 1: Information to help you<br>prepare for surgery (2 items)<br>Measure 2: How well surgeon<br>communicates with patients<br>before surgery (4 items)<br>Measure 3: Surgeon's attentiveness on | American College of<br>Surgeons, Division of<br>Advocacy and Health<br>Policy | Consensus to include this measure in the core set. |

#### **Consensus Core Set: Orthopedic Measures**

| Version 1. |
|------------|
|------------|

| Version 1.0 |                                       |  |  |
|-------------|---------------------------------------|--|--|
| М           | leasure 4: Information to help you    |  |  |
|             | recover from surgery (4               |  |  |
|             | items)                                |  |  |
| Μ           | leasure 5: How well surgeon           |  |  |
|             | communicates with patients            |  |  |
|             | after surgery (4 items)               |  |  |
| Μ           | leasure 6: Helpful, courteous, and    |  |  |
|             | respectful staff at surgeon's         |  |  |
|             | office (2 items)                      |  |  |
| Μ           | leasure 7: Rating of surgeon (1 item) |  |  |

### Future Areas for Orthopedic Measure Development

- Length of Stay
- Return to Surgery (Revision, Draining, Infection, Frozen Joint, etc.)
- Complications
- Adverse Events Surrounding Surgery (Post-operative Cellulitis, Pneumonia, etc.)
- Patient Reported Outcomes.
   *Comment:* AAOS strongly supports the use of Patient Reported Outcome Measures and once the Yale CORE/CMS PRO measures are finalized, we would like to partner with AHIP & CMS on the endorsement process.
- Functional status measures for patients undergoing orthopedic surgery
- Transitions of Care (e.g., medication reconciliation after procedure, ensuring medical records are transmitted to primary care physician, and ensuring no gaps in care)
- Emergency Department Visits
- #0052 Use of Imaging Studies for Low Back Pain